Department F. Magrassi e A. Lanzara, Second University of Naples, 80131 Napoli, Italy.
Free Radic Biol Med. 2012 May 1;52(9):1658-65. doi: 10.1016/j.freeradbiomed.2012.02.008. Epub 2012 Feb 15.
The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated with improvement in liver enzymes, insulin resistance, and liver histology, without increases in body weight. These findings warrant further investigation.
目前唯一推荐的非酒精性脂肪性肝病 (NAFLD) 治疗方法是生活方式的改变。水飞蓟宾的初步研究表明对肝功能有有益的影响。Realsil (RA) 由水飞蓟宾植物素复合物(水飞蓟宾加磷脂酰胆碱)和维生素 E 共同组成。我们报告了一项多中心、III 期、双盲临床试验,以评估 RA 在组织学证实的 NAFLD 患者中的疗效。患者按 1:1 随机分为 RA 或安慰剂 (P) 口服,每日 2 次,共 12 个月。预先规定的主要终点是随着时间的推移,临床状况的改善,肝酶血浆水平的正常化,以及超声肝脂肪变性、稳态模型评估 (HOMA) 和生活质量的改善。次要终点是肝组织学评分的改善和/或 NAFLD 评分的降低而纤维化无恶化,以及细胞因子、铁蛋白和肝纤维化标志物的血浆变化。我们治疗了 179 例 NAFLD 患者;其中 36 例还患有 HCV 阳性。41 例患者提前退出,138 例患者按方案分析(每组 69 例)。两组患者的基线特征总体上平衡良好,除了脂肪变性、门脉浸润和纤维化。不良事件 (AE) 通常是短暂的,包括腹泻、味觉障碍和瘙痒;没有记录到严重的 AE。接受 RA 治疗但未接受 P 治疗的患者,肝酶血浆水平、HOMA 和肝组织学均有显著改善。RA 组有 15%的患者体重指数正常(P 组为 2.1%)。RA 组而非 P 组的 HCV 阳性患者肝纤维化标志物有所改善。这是第一项系统评估水飞蓟宾在 NAFLD 患者中的应用的研究。RA 治疗 12 个月与改善肝酶、胰岛素抵抗和肝组织学有关,而体重没有增加。这些发现值得进一步研究。